摘要
目的探讨左乙拉西坦治疗成人难治性癫痫部分发作的疗效以及对患者免疫功能的影响。方法选取2017年1月~2019年1月辽宁省健康产业集团铁煤总医院收治的80例成人难治性癫痫部分发作患者为研究对象,采用随机数字表法分为实验组(40例)和对照组(40例)。对照组给予口服托吡酯和卡马西平,实验组在对照组的基础上口服左乙拉西坦,两组均治疗6个月。比较两组治疗效果,治疗前后免疫功能指标水平变化以及不良反应发生情况。结果实验组的总有效率为72.50%,高于对照组的47.50%,差异有统计学意义(P<0.05)。治疗后两组IgA、IgG、IgM水平均高于治疗前,且实验组IgA、IgG、IgM水平高于对照组,差异有统计学意义(P<0.05)。对照组治疗前后T细胞亚群水平比较,差异无统计学意义(P>0.05),而实验组治疗后CD3^(+)、CD4^(+)水平高于治疗前,CD8^(+)水平低于治疗前,且实验组治疗后CD3^(+)、CD4^(+)水平高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。结论左乙拉西坦对成人难治性癫痫部分发作疗效确切,可明显改善患者免疫功能,值得临床推广应用。
Objective To explore the effect of Levetiracetam on partial seizures in adults with refractory epilepsy,and its effect on the immune function of patients.Methods A total of 80 adult patients with refractory epilepsy who were admitted to Liaoning Health Industry Group Iron Coal General Hospital from January 2017 to January 2019 were selected as the research subjects.They were divided into the experimental group(40 cases)and the control group(40 cases)by random number table method.The control group was given oral Topiramate and Carbamazepine,and the experimental group was given Levetiracetam on the basis of the control group.Both groups were treated for 6 months.The effect of treatment,changes of immune function indexes before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the experimental group was 72.50%,which was higher than 47.50%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of IgA,IgG and IgM in the two groups were higher than before,and the levels of IgA,IgG and IgM in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in T cell subsets in the control group before and after treatment(P>0.05).After treatment,the levels of CD3^(+)and CD4^(+)in the experimental group were higher than before treatment,the level of CD8^(+)was lower than before treatment,and the levels of CD3^(+)and CD4^(+)in the experimental group were higher than those of the control group and the level of CD8^(+)was lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion The efficacy of Levetiracetam in the treatment of refractory epilepsy in adults is definite and can significantly improve the immune function of patients,which is worthy of clinical application.
作者
尚小琳
SHANG Xiao-lin(Department of Neurology,Liaoning Health Industry Group Iron Coal General Hospital,Liaoning Province,Diaobingshan112700,China)
出处
《中国当代医药》
CAS
2021年第9期62-64,共3页
China Modern Medicine
